Hong Kong, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BUUU Group Limited (Nasdaq: BUUU) (the “Company”), an established meetings, incentives, conferences and exhibitions (“MICE”) solutions provider based in Hong Kong , today announced the closing of its initial public offering (the “Offering”) of 1,500,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $4.00 per Class A Ordinary Share (the “Offering Price”).
FREMONT, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today reported financial results for the second quarter ended June 30, 2025.
NICOSIA, Cyprus, Aug. 14, 2025 /PRNewswire/ -- Bookmap, a market-leading platform for order flow and liquidity visualization, has partnered with Tradier to offer futures...
Binaural Technologies’ The Brain Song offers a 17-minute gamma brainwave and BDNF support audio program for adults seeking natural memory, focus, and cognitive resilience without pills or complex routines in 2025.
Binaural Technologies’ The Brain Song offers a 17-minute gamma brainwave and BDNF support audio program for adults seeking natural memory, focus, and cognitive resilience without pills or complex routines in 2025.
Milestone Reflects Growing Demand for High-Conviction, Tactical Exposure to the Innovation Economy.
NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for...
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.
Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets
Increased Total...
Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets
Increased Total...